ScinoPharm has completed construction of a R&D process-development center and a multipurpose API cGMP manufacturing plant in Changshu, China.
A total of $113 million was invested in this facility. The new plant will work together with ScinoPharm Taiwan in the production of new and generic drugs for the international market as well as supply the local Chinese market. The plant has already received drug production licenses from the Chinese FDA for four APIs products. The plant will also serve as the base for the company to develop its API business in China. ScinoPharm has already developed nine of the top 20 oncological products used in China, according to the company.
The Changshu plant is equipped to manufacture high-potency, antitumor, hormonal-active pharmaceutical ingredients and intermediates in highly contained facilities. In addition, the plant is also able to manufacture new products in smaller quantities for sales evaluations and for GMP samples.
The company also has purchased an additional 108 acres of adjoining property to be used for the development of future API production lines and for the construction of future formulation production plants.